Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN versus GEMIFLOXACIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN versus GEMIFLOXACIN MESYLATE.
CIPROFLOXACIN vs GEMIFLOXACIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
400 mg IV every 12 hours or 500 mg orally every 12 hours for uncomplicated infections; 400 mg IV every 8 hours or 750 mg orally every 12 hours for severe/complicated infections.
320 mg orally once daily for 7-14 days
None Documented
None Documented
4 hours (3-5 hours) in normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 20-50 mL/min) and 12-24 hours in severe impairment (CrCl <20 mL/min)
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Renal (50-70% unchanged via glomerular filtration and tubular secretion); fecal (15-25% via biliary and transintestinal elimination); <1% as metabolites
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic